On-chip drug discovery, built for the AI era
On-Chip Protein Synthesis and HT-SPR Kinetics at Scale
Drug discovery and AI model development are currently constrained by fragmented experimental workflows: microwell plate-based synthesis, protein purification and analysis across disconnected instruments.
SPOC unifies that process on a single on-chip library, for SPR or MALDI-MS analysis. We synthesize up to 1,152 protein or drug variants directly on one biosensor chip and measure them simultaneously with high-throughput SPR. The result is a rich, decision-ready datasets with full kinetic binding profiles, ka, kd, KD, t½ and Rmax, delivered in weeks instead of months, at a fraction of the cost.
The Challenges of Proteins Study
Current recombinant protein workflows for producing and studying protein kinetics are complex, time-consuming, and expensive. This presents a significant barrier to understanding the causes of diseases, as well as achieving early detection and cure.
Binding to Assessing Developability, On the Same On-chip Library
A transformative technology that produces 1000s of full-length folded proteins on a biosensor chip, enabling the evaluation of protein binding kinetics at just 10% of the current cost. This innovative approach is set to revolutionize AI drug design, pre-clinical drug development, vaccines, protein biomarker discovery for precision medicine and diagnostics.
Protein Nano Factory
We have developed an automated system that synthesizes proteins directly from DNA in tens of thousands and nano-wells, capture-purified onto biosensor chips. Leveraging surface plasmon resonance (SPR) technology, SPOC simultaneously measures the binding kinetics of thousands of on-chip proteins.
Accelerate your AI Drug Design with our Lab-in-the Loop Platform
On-chip drug discovery, built for the AI era
On-Chip Protein Synthesis and HT-SPR Kinetics at Scale
Drug discovery and AI model development are currently constrained by fragmented experimental workflows: microwell plate-based synthesis, protein purification and analysis across disconnected instruments.
SPOC unifies that process on a single on-chip library, for SPR or MALDI-MS analysis. We synthesize up to 1,152 protein or drug variants directly on one biosensor chip and measure them simultaneously with high-throughput SPR. The result is a rich, decision-ready datasets with full kinetic binding profiles, ka, kd, KD, t½ and Rmax, delivered in weeks instead of months, at a fraction of the cost.
Wet-Lab Validation at the Speed of AI Drug Design
AI models can generate candidates at scale, but meaningful progress depends on fast, high-quality experimental validation and feedback. SPOC delivers large, consistent sequence-to-kinetics datasets with full kinetic profiles and expression titers across up to 1,152 variants per library, far beyond just sparse single-concentration signals.
Binding to Assessing Developability, On the Same On-chip Library
The same on-chip library can power far more than binding screens. SPOC enables expression titer measurement, kinetic parameter-based ranking, epitope mapping, 8-panel polyreactivity profiling, specificity screening against homologs and follow-on developability assessments such as aggregation propensity and stress stability, all from the same on-chip library. A fuller picture of candidate quality at library scale, before lead nomination.
Unlocking Richer Biology to Reduce Attrition Rates
Complete characterization at library scale changes which candidates advance. By delivering full kinetics, developability and translational screening in a single campaign, SPOC shifts lead selection from incomplete signals to a fuller picture of candidate quality, helping reduce the attrition that begins at lead nomination and surfaces in the clinic.
Accelerate your AI Drug Design with our Lab-in-the Loop Platform
2
3
4
5
Unlocking Richer Biology to Reduce Attrition Rates
Unlocking Richer Biology to Reduce Attrition Rates
Complete characterization at library scale changes which candidates advance. By delivering full kinetics, developability and translational screening in a single campaign, SPOC shifts lead selection from incomplete signals to a fuller picture of candidate quality, helping reduce the attrition that begins at lead nomination and surfaces in the clinic.
Complete characterization at library scale changes which candidates advance. By delivering full kinetics, developability and translational screening in a single campaign, SPOC shifts lead selection from incomplete signals to a fuller picture of candidate quality, helping reduce the attrition that begins at lead nomination and surfaces in the clinic.
Library-on-Library Datasets for AI Drug Design
Library-on-Library Datasets for AI Drug Design
AI drug discovery will be shaped not only by better models, but by better training data. SPOC generates large-scale, high-resolution biological datasets that link sequence, expression, kinetics, specificity and developability across entire on-chip libraries. The result is a new class of model-ready experimental data for pre-training and improving AI systems in biologics discovery and design.
AI drug discovery will be shaped not only by better models, but by better training data. SPOC generates large-scale, high-resolution biological datasets that link sequence, expression, kinetics, specificity and developability across entire on-chip libraries. The result is a new class of model-ready experimental data for pre-training and improving AI systems in biologics discovery and design.
Kinetic Optimization Across Every Modality
Kinetic Optimization Across Every Modality
Optimal binding kinetics depend on the modality. High-affinity binders suit mAb programs like Keytruda and Humira; moderate affinities reduce T cell exhaustion risk in CAR-T and BiTE formats; ADCs require precise kon/koff tuning to minimize dose-limiting off-target toxicities. SPOC delivers the full kinetic profile (ka, kd, KD, t½, Rmax) across entire variant panels, so the selection decision is made on complete kinetic data, not just KD alone.
Optimal binding kinetics depend on the modality. High-affinity binders suit mAb programs like Keytruda and Humira; moderate affinities reduce T cell exhaustion risk in CAR-T and BiTE formats; ADCs require precise kon/koff tuning to minimize dose-limiting off-target toxicities. SPOC delivers the full kinetic profile (ka, kd, KD, t½, Rmax) across entire variant panels, so the selection decision is made on complete kinetic data, not just KD alone.
For decades, drug discovery has relied on fragmented, one-assay-at-a-time workflows.
SPOC is changing that for the new AI-native world by bringing Moore’s Law-like scalability to the experimental layer.
For decades, drug discovery has relied on fragmented, one-assay-at-a-time workflows.
SPOC is changing that for the new AI-native world by bringing Moore’s Law-like scalability to the experimental layer.
Early Access to the SPOC Platform is now open. See Below for more information.
Early Access to the SPOC Platform is now open. See Below for more information.
SPOC Early Access Program (EAP)
SPOC Early Access Program (EAP)
Our SPOC Early Access Program (EAP) is now open. We are currently taking on limited pilot projects from select customers focused on traditional & AI aided drug discovery and generating proprietary data for AI model training. Please contact us to learn how SPOC can help your product development.
Our SPOC Early Access Program (EAP) is now open. We are currently taking on limited pilot projects from select customers focused on traditional & AI aided drug discovery and generating proprietary data for AI model training. Please contact us to learn how SPOC can help your product development.
For more information on the SPOC platform, get in touch:
Contact Us
1600 Adams Drive
Suite 236
Menlo Park, CA 94025
7201 E Henkel Way
Suite 285
Scottsdale, AZ 85255
480-219-9506
For more information on the SPOC platform, get in touch:
Contact Us
1600 Adams Drive
Suite 236
Menlo Park, CA 94025
7201 E Henkel Way
Suite 285
Scottsdale, AZ 85255
480-219-9506
Privacy & Conditions
All rights reserved © 2024
